Cytokine interleukin 17E (IL-17E) has been found to effective in a number of solid tumors, including melanoma, breast, colon, pancreatic, and non-small cell lung cancers, Lorus Therapeutics Inc announced.

Rexahn Pharmaceuticals has been granted a patent for its novel anti-cancer compound to overcome drug resistance, RX-3117 by the European Patent Office.

A new safer drug toxicity test to minimize the drug failure rates in clinical trials for cancer treatmants has been developed.